Literature DB >> 28298943

Hepatic vein transit time of second-generation ultrasound contrast agent: new tool in the assessment of portal hypertension.

Siciliani Luisa1, Giovanna Vitale2, Anna Rita Sorbo2, Pompili Maurizio2, Rapaccini Gian Lodovico2.   

Abstract

PURPOSE: It has been demonstrated that Doppler waveform of the hepatic vein (normally triphasic) is transformed into a biphasic or monophasic waveform in cirrhotic patients. The compressive mechanism of liver tissue has been considered up till now the cause of this change. Moreover, cirrhotics show, after USCA injection, a much earlier HVTT due to intrahepatic shunts. Our aim was to prospectively evaluate the correlation between Doppler pattern of hepatic vein and HVTT of a second-generation USCA; we also correlated HVTT with the most common indexes of portal hypertension.
METHODS: We enrolled 38 participants: 33 cirrhotics and 5 healthy controls. Doppler shift signals were obtained from the right hepatic vein. To characterize the hepatic vein pattern, we used the hepatic vein waveform index (HVWI). This index becomes >1 with the appearance of the triphasic waveform. We recorded a clip from 20 s before to 2 min after a peripheral intravenous bolus injection of 2.4 ml of USCA (sulfur hexafluoride).The time employed by USCA to cross the liver from the hepatic artery and portal vein to the hepatic vein was defined as HA-HVTT and PV-HVTT, respectively.
RESULTS: Cirrhotics with low HVWI showed an earlier transit time; participants with higher HVWI had a longer transit time (p < 0.001). HVTT was earlier as MELD, Child-Pugh score and spleen diameter increased. Patients with ascites and varices of large size had significantly shorter transit times.
CONCLUSIONS: Abnormal hepatic vein Doppler waveform in cirrhotic patients could be due to intrahepatic shunts. HVTT could be useful in the non-invasive evaluation of portal hypertension.

Entities:  

Keywords:  Cirrhosis; Hepatic vein transit times; Hepatic vein waveform; Non-invasive procedure; Portal hypertension; Ultrasound contrast agent

Mesh:

Substances:

Year:  2016        PMID: 28298943      PMCID: PMC5334268          DOI: 10.1007/s40477-016-0226-1

Source DB:  PubMed          Journal:  J Ultrasound        ISSN: 1876-7931


  32 in total

1.  Circulatory changes in chronic liver disease.

Authors:  J F MURRAY; A M DAWSON; S SHERLOCK
Journal:  Am J Med       Date:  1958-03       Impact factor: 4.965

2.  Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C.

Authors:  C F Dietrich; J H Lee; R Gottschalk; G Herrmann; C Sarrazin; W F Caspary; S Zeuzem
Journal:  AJR Am J Roentgenol       Date:  1998-08       Impact factor: 3.959

3.  Assessment of tricuspid regurgitation by pulsed Doppler ultrasonography of the hepatic veins.

Authors:  F Pennestrí; F Loperfido; M P Salvatori; R Mongiardo; A Ferrazza; P Guccione; U Manzoli
Journal:  Am J Cardiol       Date:  1984-08-01       Impact factor: 2.778

4.  A peek at the Child-Turcotte classification.

Authors:  H O Conn
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

5.  Association between duplex Doppler sonographic flow pattern in right hepatic vein and various liver diseases.

Authors:  A von Herbay; T Frieling; D Häussinger
Journal:  J Clin Ultrasound       Date:  2001-01       Impact factor: 0.910

6.  Contrast-enhanced color Doppler US in malignant portal vein thrombosis.

Authors:  P Ricci; V Cantisani; F Biancari; F M Drud; M Coniglio; A Di Filippo; F Fasoli; R Passariello
Journal:  Acta Radiol       Date:  2000-09       Impact factor: 1.990

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

8.  Intrahepatic peripheral cholangiocarcinoma (IPCC): comparison between perfusion ultrasound and CT imaging.

Authors:  M D'Onofrio; F Vecchiato; V Cantisani; E Barbi; M Passamonti; P Ricci; R Malagò; N Faccioli; G Zamboni; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2008-02-25       Impact factor: 3.469

9.  Liver cirrhosis: changes of Doppler waveform of hepatic veins.

Authors:  L Bolondi; S Li Bassi; S Gaiani; G Zironi; G Benzi; V Santi; L Barbara
Journal:  Radiology       Date:  1991-02       Impact factor: 11.105

10.  Contrast enhancement ultrasound application in focal liver lesions characterization: a retrospective study about guidelines application (SOCEUS-CEUS survey).

Authors:  Mirko D'Onofrio; Laura Romanini; Carla Serra; Fabrizio Magnolfi; Michele Bertolotto; Emilio Quaia; Gino Puntel; Alessandro Colleoni; Erica Fiorini; Cristina Cenci; Elena Santi; Valentina Ciaravino; Francesco Laffranchi; Orlando Catalano; Vito Cantisani; Fabrizio Calliada; Lorenzo Derchi
Journal:  J Ultrasound       Date:  2015-11-02
View more
  3 in total

1.  Spleen Transient Elastography and Damping Index Identify a Subgroup of Patients Without an Acute or Chronic Response to Beta-Blockers.

Authors:  Elba Llop; Christie Perelló; Teresa Fontanilla; Juan de la Revilla; Marta Hernández Conde; Marta López; Javier Minaya; Carlos Ferre; Javier Abad; Carlos Fernández Carrillo; José Luís Martínez; Natalia Fernández Puga; María Trapero; Ismael El Hajra; Elena Santos; José Luis Calleja
Journal:  Front Med (Lausanne)       Date:  2022-06-22

2.  Correlation between portal vein diameter and craniocaudal length of the spleen.

Authors:  Shah Zaman; Syed Amir Gilani; Raham Bacha; Iqra Manzoor; Zain Ul Hasan
Journal:  J Ultrason       Date:  2019-12-31

3.  Hepatic arterialization can predict the development of collateral veins in patients with HCV-related liver disease.

Authors:  Noritaka Wakui; Hidenari Nagai; Yu Ogino; Kojiro Kobayashi; Daigo Matsui; Takanori Mukozu; Yasushi Matsukiyo; Teppei Matsui; Yasuko Daido; Koichi Momiyama; Mie Shinohara; Takahide Kudo; Kenichi Maruyama; Yasukiyo Sumino; Yoshinori Igarashi
Journal:  J Ultrasound       Date:  2018-10-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.